Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
25
1
2022
medline:
15
4
2022
entrez:
24
1
2022
Statut:
ppublish
Résumé
Direct-acting antivirals (DAAs) have been approved for treating chronic hepatitis C virus (HCV) in children and adolescents. Although DAAs have been used in real-world settings for the treatment of HCV monoinfected adolescents, few reports of real-world use of DAAs in children and adolescents who are coinfected with human immunodeficiency virus (HIV) are available. We evaluated the real-world safety and effectiveness of DAAs in HIV/HCV coinfected adolescents from the Ukraine Paediatric HIV Cohort Study including all those for whom treatment outcomes were available by April 2021. Overall, 6 coinfected adolescents had received DAA treatment; 4 with sofosbuvir/ledipasvir (SOF/LDV), 1 with SOF/LDV+ribavirin, and 1 with SOF/daclatasvir. No patient discontinued treatment due to adverse events and no serious adverse events were reported. All 6 patients achieved sustained virologic response by 12 weeks after the end of therapy. DAA treatment was well tolerated and effective in adolescents with HIV/HCV coinfection in a real-world setting.
Identifiants
pubmed: 35067642
doi: 10.1097/INF.0000000000003467
pii: 00006454-202205000-00013
doi:
Substances chimiques
Antiviral Agents
0
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
417-419Subventions
Organisme : Medical Research Council
ID : MC_UU_00004/03
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
C.T. has previously received grant funding from ViiV Healthcare and BMS (through Penta Foundation). I.J.C. reports grants from Abbvie, Bristol Myers Squibb, Gilead, Janssen Pharmaceuticals, and ViiV Healthcare (through the Penta Foundation). The remaining authors have no conflicts of interest to disclose.
Références
Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477–487.
Malik F, Bailey H, Chan P, et al. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. JHEP Rep. 2021;3:100227.
Turkova A, Giacomet V, Goetghebuer T, et al. HCV treatment in children and young adults with HIV/HCV co-infection in Europe. J Virus Erad. 2015;1:179–184.
Thorne C, Eppicc C. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. AIDS. 2017;31:127–135.
Amele S, Peters L, Rodger A, et al.; EuroSIDA study group. Effectiveness and safety of interferon-free direct-acting antiviral Hepatitis C virus therapy in HIV/Hepatitis C virus coinfected Individuals: results from a Pan-European Study. J Acquir Immune Defic Syndr. 2021;86:248–257.
Indolfi G, Bartolini E, Serranti D, et al. Hepatitis C in children co-infected with human immunodeficiency virus. J Pediatr Gastroenterol Nutr. 2015;61:393–399.
Carrasco I, Sainz T, Frick MA, et al.; the Pediatric National AIDS Research Network of Spain (CoRISpe) integrated in the Translational Research Network in Pediatric Infectious Diseases (RITIP). Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients. J Viral Hepat. 2020;27:955–958.
Kamal EM, El-Shabrawi M, El-Khayat H, et al. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. Liver Int. 2020;40:319–323.
Serranti D, Nebbia G, Cananzi M, et al. Efficacy of Sofosbuvir/Ledipasvir in adolescents with chronic hepatitis C genotypes 1, 3, and 4: A Real-world Study. J Pediatr Gastroenterol Nutr. 2021;72:95–100.
Harris PA, Taylor R, Minor BL, et al.; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Pokorska-Śpiewak M, Dobrzeniecka A, Ołdakowska A, et al. Effective treatment of chronic hepatitis C virus infection with Ledipasvir/Sofosbuvir in 2 teenagers with HIV coinfection. Pediatr Infect Dis J. 2021; 40:1–3.
World Health Organization. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection . World Health Organization; 2018.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.
University of Liverpool. Liverpool HIV Interactions [Internet]. Available at: https://www.hiv-druginteractions.org/checker . Accessed November 3, 2021.